Streetbeat News

Analyst Ratings

SRPT

JP Morgan analyst Anupam Rama maintains an Overweight rating on Sarepta Therapeutics (NASDAQ:SRPT) but lowers the price target from $211 to $115.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 8:37 pm

PRMW

JP Morgan analyst Andrea Teixeira maintains an Overweight rating on Primo Water (NYSE:PRMW) but has lowered the price target from $20 to $18.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 8:35 pm

QUAD

Quad/Graphics reported Q3 2023 earnings of $0.11 per share, beating the analyst consensus estimate of $0.05 by 120 percent. However, this is a 65.63 percent decrease from the same period last year. The company's quarterly sales of $700.20 million missed the analyst consensus estimate of $732.40 million by 4.40 percent, marking a 15.63 percent decrease from the previous year.

Portfolio Pulse from vinayak@benzinga.com

October 31, 2023 | 8:35 pm

PAG

JP Morgan analyst Rajat Gupta maintains an Underweight rating on Penske Automotive Group (NYSE:PAG) and has lowered the price target from $145 to $140.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 8:32 pm

ON

JP Morgan analyst Harlan Sur has maintained a Neutral rating on ON Semiconductor (NASDAQ:ON) and lowered the price target from $118 to $95.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 8:31 pm

GPN

A significant amount of unusual options activity has been observed for Global Payments (NYSE:GPN), with a majority of investors taking a bullish stance. The targeted price range for Global Payments over the last 3 months is from $90.0 to $110.0. The current price of GPN is up 2.33% at $106.22. Several financial institutions have downgraded their ratings on Global Payments, with price targets ranging from $130 to $154.

Portfolio Pulse from Benzinga Insights

October 31, 2023 | 8:31 pm

MDT

A large investor has taken a bullish stance on Medtronic (NYSE:MDT), as evidenced by a significant position in the company's options. The overall sentiment of these big-money traders is split between 60% bullish and 40% bearish. The whales have been targeting a price range from $50.0 to $82.5 for Medtronic over the last 3 months. The current price of MDT is up 0.84% at $70.56.

Portfolio Pulse from Benzinga Insights

October 31, 2023 | 8:30 pm

MNST

JP Morgan analyst Andrea Teixeira has maintained an Overweight rating on Monster Beverage (NASDAQ:MNST) but lowered the price target from $65 to $57.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 8:29 pm

CHGG

JP Morgan analyst Doug Anmuth maintains a Neutral rating on Chegg (NYSE:CHGG) and lowers the price target from $12 to $10.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 8:09 pm

RTX

A significant amount of unusual options activity has been detected for Raytheon Technologies Corporation (RTX), with a mix of bullish and bearish stances. The trades have targeted a price range of $75.0 to $100.0 for RTX over the last 3 months. The current price of RTX is up 3.37% at $81.22. Morgan Stanley maintains an Equal-Weight rating on RTX with a price target of $86, while UBS has downgraded its action to Neutral with a price target of $80.

Portfolio Pulse from Benzinga Insights

October 31, 2023 | 8:09 pm